Fuente: FierceBiotech John Tsai, M.D., is rounding out his global drug development resume. Immediately after landing at Daiichi Sankyo, the pharma veteran finds himself leading the R&D portion of the antibody-drug conjugate specialist’s new five-year plan, which aims to lay the groundwork for Daiichi to become a global top 5 oncology company by 2035.